Overview
TPST market data
Price History
TPST price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$6.33 Diluted earnings per share over the trailing twelve months.
- Beta
- -1.62 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.84 – $12.23 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $13.9 · P/B 2.12 · P/S 46.24.
Company News
8-K filing — Tempest Therapeutics, Inc. (TPST)SEC EDGAR · Jul 28, 2026, 8:50 PM
Tempest And Senlang To Collaborate To Develop Tempest’s Proprietary TPST-4003 Product Candidate, Beginning With IIT In China Evaluating TPST-4003 In ~10 Patients With MG Or MS; Expects First Patient Enrollment And Dosing To Occur In Q4 Of 2026Benzinga · Jul 21, 2026, 11:10 AM
Tempest Unveils Next-Gen In Vivo CAR-T Platform; To Advance TPST-4003 Into Q4 2026 Trial In MG, MS PatientsBenzinga · Jul 15, 2026, 11:04 AM
Tempest Therapeutics Files Prospectus For Offering 2.427M Common Shares On Behalf Of Selling ShareholdersBenzinga · Jun 26, 2026, 8:10 PM
Tempest Therapeutics Nicholas Maestas Resigns As CFO Effective June 5, 2026; Appoints Justin Trojanowski As Principal Financial Officer Effective June 5, 2026Benzinga · Jun 4, 2026, 9:10 PM
Tempest Therapeutics Announces Exercise Of Warrants On 1,172,414 Shares At $1.73/ShareBenzinga · May 29, 2026, 12:03 PM
Tempest Therapeutics Q1 Adj. EPS $(0.50) Misses $(0.28) EstimateBenzinga · May 14, 2026, 9:23 PM